The FINANCIAL -- GlaxoSmithKline announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Nimenrix for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

According to GlaxoSmithKline, a CHMP positive opinion is one of the final steps before regulatory approval. As part of its assessment, CHMP reviewed immunogenicity and safety data from more than 8000 patients aged 1 year and above. The clinical program included 17 clinical studies conducted in 17 countries worldwide.

Related Stories

• FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine
• Pfizer Names Olivier Brandicourt as President and General Manager
• Janssen Healthcare Innovation Announces Discharge Decision Support System Winner